Israel’s heavily indebted Teva Pharmaceutical Industries (TEVA.TA) on Thursday raised its financial outlook for 2018 after reporting a smaller than expected drop in first-quarter net profit and revenue. Teva also said that while it does not expect to receive approval for its migraine treatment fremanezumab by mid-June, as had been hoped, it does expect the key drug to gain approval in time for launch before the end of 2018. Analysts had forecast Teva (TEVA.N) would earn 67 cents a share excluding one-offs on revenue of $4.8 billion, according to Thomson Reuters I/B/E/S. …read more
Source:: Yahoo Finance
